Selected research
Industry Growth & Trends
Global Non Hodgkin Lymphoma (NHL) Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Non Hodgkin Lymphoma (NHL) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Non Hodgkin Lymphoma (NHL) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Non Hodgkin Lymphoma (NHL) market include Bristol Myers Squibb, Celgene, F. Hoffmann-La Roche, Bayer, GlaxoSmithKline, Eli Lilly, Merck and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Non Hodgkin Lymphoma (NHL) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Non Hodgkin Lymphoma (NHL) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Non Hodgkin Lymphoma (NHL) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Non Hodgkin Lymphoma (NHL).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Non Hodgkin Lymphoma (NHL) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Non Hodgkin Lymphoma (NHL) Market by Company
Bristol Myers Squibb
Celgene
F. Hoffmann-La Roche
Bayer
GlaxoSmithKline
Eli Lilly
Merck
Johnson & Johnson
Non Hodgkin Lymphoma (NHL) Segment by Type
Standard
Exellent
Non Hodgkin Lymphoma (NHL) Segment by Application
Hosptial
Clinic
Non Hodgkin Lymphoma (NHL) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non Hodgkin Lymphoma (NHL) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non Hodgkin Lymphoma (NHL) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non Hodgkin Lymphoma (NHL).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Non Hodgkin Lymphoma (NHL) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Standard
- Exellent
Applications
- Hosptial
- Clinic
Companies covered
- Bristol Myers Squibb
- Celgene
- F. Hoffmann-La Roche
- Bayer
- GlaxoSmithKline
- Eli Lilly
- Merck
- Johnson & Johnson
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Non Hodgkin Lymphoma (NHL) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2032)
- 1.4.1 Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2021-2026)
- 1.4.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Region (2027-2032)
- 1.5 Key Regions Non Hodgkin Lymphoma (NHL) Market Size (2021-2032)
- 1.5.1 North America Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (2021-2032)
2 Non Hodgkin Lymphoma (NHL) Market by Type
- 2.1 Type Introduction
- 2.1.1 Standard
- 2.1.2 Exellent
- 2.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Type
- 2.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Non Hodgkin Lymphoma (NHL) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Non Hodgkin Lymphoma (NHL) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Non Hodgkin Lymphoma (NHL) Market Size by Regions
- 2.3.1 North America Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Type (2021-2026)
3 Non Hodgkin Lymphoma (NHL) Market by Application
- 3.1 Type Introduction
- 3.1.1 Hosptial
- 3.1.2 Clinic
- 3.2 Global Non Hodgkin Lymphoma (NHL) Market Size by Application
- 3.2.1 Global Non Hodgkin Lymphoma (NHL) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Non Hodgkin Lymphoma (NHL) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Non Hodgkin Lymphoma (NHL) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Non Hodgkin Lymphoma (NHL) Market Size by Regions
- 3.3.1 North America Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Non Hodgkin Lymphoma (NHL) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Non Hodgkin Lymphoma (NHL) Industry Trends
- 4.2 Non Hodgkin Lymphoma (NHL) Industry Drivers
- 4.3 Non Hodgkin Lymphoma (NHL) Industry Opportunities and Challenges
- 4.4 Non Hodgkin Lymphoma (NHL) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Non Hodgkin Lymphoma (NHL) Revenue (2021-2026)
- 5.2 Global Non Hodgkin Lymphoma (NHL) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Non Hodgkin Lymphoma (NHL) Key Company Headquarters & Area Served
- 5.4 Global Non Hodgkin Lymphoma (NHL) Company, Product Type & Application
- 5.5 Global Non Hodgkin Lymphoma (NHL) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Non Hodgkin Lymphoma (NHL) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Non Hodgkin Lymphoma (NHL) Players Market Share by Revenue in 2025
- 5.6.3 2025 Non Hodgkin Lymphoma (NHL) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bristol Myers Squibb
- 6.1.1 Bristol Myers Squibb Company Information
- 6.1.2 Bristol Myers Squibb Business Overview
- 6.1.3 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bristol Myers Squibb Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.1.5 Bristol Myers Squibb Recent Developments
- 6.2 Celgene
- 6.2.1 Celgene Company Information
- 6.2.2 Celgene Business Overview
- 6.2.3 Celgene Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Celgene Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.2.5 Celgene Recent Developments
- 6.3 F. Hoffmann-La Roche
- 6.3.1 F. Hoffmann-La Roche Company Information
- 6.3.2 F. Hoffmann-La Roche Business Overview
- 6.3.3 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 F. Hoffmann-La Roche Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.3.5 F. Hoffmann-La Roche Recent Developments
- 6.4 Bayer
- 6.4.1 Bayer Company Information
- 6.4.2 Bayer Business Overview
- 6.4.3 Bayer Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bayer Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.4.5 Bayer Recent Developments
- 6.5 GlaxoSmithKline
- 6.5.1 GlaxoSmithKline Company Information
- 6.5.2 GlaxoSmithKline Business Overview
- 6.5.3 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 GlaxoSmithKline Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.5.5 GlaxoSmithKline Recent Developments
- 6.6 Eli Lilly
- 6.6.1 Eli Lilly Company Information
- 6.6.2 Eli Lilly Business Overview
- 6.6.3 Eli Lilly Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Eli Lilly Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.6.5 Eli Lilly Recent Developments
- 6.7 Merck
- 6.7.1 Merck Company Information
- 6.7.2 Merck Business Overview
- 6.7.3 Merck Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Merck Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.7.5 Merck Recent Developments
- 6.8 Johnson & Johnson
- 6.8.1 Johnson & Johnson Company Information
- 6.8.2 Johnson & Johnson Business Overview
- 6.8.3 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Johnson & Johnson Non Hodgkin Lymphoma (NHL) Product Portfolio
- 6.8.5 Johnson & Johnson Recent Developments
7 North America
- 7.1 North America Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
- 7.3 North America Non Hodgkin Lymphoma (NHL) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
- 8.3 Europe Non Hodgkin Lymphoma (NHL) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
- 10.3 South America Non Hodgkin Lymphoma (NHL) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Non Hodgkin Lymphoma (NHL) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst